Sage Journals: Discover world-class research

Abstract

The numbers of clinical trial consultations and approved NDAs in FY2007 increased more than 50% compared with FY2004, when the PMDA was established.

The strategy of new drug development has changed significantly; in particular, simultaneous global development has accelerated dramatically in Asia, except in Japan. Based on this situation, the PMDA and MHLW clarified their intention to encourage the pharmaceutical industry to conduct multinational clinical trials from the early stage of clinical development in September 2007. As a result, the number of multinational clinical trials including Japan began to increase quickly.

With regard to the review time of NDAs, it still takes longer than that of FDA or EMEA. Although the situation has begun to improve, the PMDA still needs to further shorten it. The PMDA initiated a new plan starting in April 2007 to add more than 200 reviewers within a period of approximately three years in order to resolve the issue of drug lag.

Keywords

Japan Pharmaceuticals and Medical Devices Agency (PMDA)Global development Multinational clinical trial Drug lag

Get full access to this article

View all access options for this article.

References

Pharmaceuticals and Medical Devices Agency. About PMDA objective. Available at: http://www.pmda.go.jp/english/about/objective.html. AccessedMay 1, 2008.

Ono

Yoshioka

Asaka

Tamura

The review of new drug applications in Japan: the decline in approval times after the introduction of an internalized review system. Drug Inf J. 2006;39:279–290.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: ethnic factors in the acceptability of foreign clinical data (E5(R1)), step 4, February 1998. Available at: http://www.ich.org/LOB/media/MEDIA481.pdf. Accessed May 1, 2008.

Naito

Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000;38(2):80–86.

Uyama

Shibata

Nagai

Hanaoka

Toyoshima

Mori

Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther. 2005;78(2): 102–113.

Japanese Pharmaceutical Manufacturer Association Office of Pharmaceutical Industry Research. Research paper no. 31, May 2006. In Japanese. Available at: http://www.jpma.or.jp/opir/research/paper-31.pdf. Accessed May 1, 2008.

The Interim Report of Clinical Trial Issue Review Committee. September 2006. Available at: http://www.pmda.go.jp/english/topics/pdf/clinical.pdf. Accessed May 1, 2008.

ICH-E5: ethnic factors in the acceptability of foreign clinical data questions & answers (R1). June 2, 2006. Available at: http://www.ich.org/LOB/media/MEDIA1194.pdf. Accessed May 1, 2008.

Basic principles on global clinical trials. Informal translation by PMDA of Notification no. 0928010, Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministory of Health, Labor and Welfare. September 28, 2007. Available at: http://www.pmda.go.jp/operations/notice/2007/file/0928010-e.pdf. Accessed May 1, 2008.

10.

Presentation by Young-Chan Kim (Korean FDA) at East Asian Pharmaceutical Regulatory Symposium 2008. Available at: http://www2.convention.co.jp/eaprs2008ph/presen/0414-C-04.pdf. Accessed May 1, 2008.

11.

Presentation by Herng-Der Chern (CDE Taiwan) at the fifth International Federation of Pharmaceutical Manufacturers Associations ARC 2008, Available at: http://www.ifpma.org/arc-2008/uploads/media/Chern_GDD_Breakout_2.pdf. Accessed May 1, 2008.

12.

Presentation by Kazuhiko Mori (PMDA Japan) at the fifth IFPMA ARC 2008. Available at: http://www.ifpma.org/arc-2008/uploads/media/Mori_GDD_Breakout_2.pdf. Accessed May 2, 2008.

13.

Council for Science and Technology Policy. Institutional Reform for Promoting Science and Technology and Passing on the Benefits to Society. December 25, 2006. In Japanese. Available at: http://www8.cao.go.jp/cstp/output/iken061225-1.pdf. Accessed May 2, 2008.

14.

Pharmaceuticals and Medical Devices Agency. Actual operation results for FY2006. Annual Report FY2006. Available at: http://www.pmda.go.jp/english/reports/pdf/2006/2title_FY2006.pdf. Accessed May 2, 2008.

15.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories E15, step 4, November 2007. Available at: http://www.ich.org/LOB/media/MEDIA3383.pdf. Accessed May 2, 2008.

16.

East Asian Pharmaceutical Regulatory Symposium 2008. Tokyo, April 2008. Available at: http://www2.convention.co.jp/eaprs2008ph/.Accessed May 2, 2008.

Recent Approaches by the PMDA to Promoting New Drug Development: Change in the Status of the PMDA in Relation to New Drug Development over the Last Five Years

Abstract

Keywords

Get full access to this article

References